Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Nestle Group
Nestle Group
Activities:
Active Nutrition
Food
Nutraceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Scleroderma treatment by Certa Therapeutics granted US FDA fast track
FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
Naobios and Sumagen sign exclusive partnership to develop HIV vaccine
Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
Rapid increase in purchasing teams expected at CPHI North America
Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
Bio-Rad and Oncocyte partner to commercialise transplant monitoring with Droplet Digital PCR
The collaboration aims to provide researchers with tools to enable transformational monitoring of key biomarkers in solid tissue transplants
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Ingredients
Nestlé tackles phenylketonuria with Codexis enzyme
Codexis announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialisation of the orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU)
Ingredients
Nestlé agrees joint venture with China MediTech
NSP will develop nutritional and medical products derived from botanical plants
Finance
Nestlé Health Science to buy Prometheus Laboratories
Makes a strategic move into gastrointestinal diagnostics
Finance
Novartis and Alcon agree merger terms
Will create a new eyecare group with Ciba Vision and ophthalmic medicines business
Novartis to buy rest of Alcon
<p>Swiss pharmaceutical group Novartis is to purchase 52% of eye care specialist Alcon from Nestle in the second stage of a US$38.5bn deal agreed in 2008.</p>
Media
Alcon to acquire ESBATech
<p>Eye care specialist Alcon is to acquire Swiss biotechnology company ESBATech, based in Zurich, for US$150m in cash.</p>
Subscribe now